CRISPR THERAPEUTICS AG

(CRSP)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
66.96 USD   +2.78%
06/23Oppenheimer Adjusts CRISPR Therapeutics Price Target to $122 From $150, Maintains Outperform Rating
MT
06/23Evercore ISI Downgrades CRISPR Therapeutics to In Line From Outperform, Lowers Price Target to $60 From $66
MT
06/22Chardan Adjusts CRISPR Therapeutics' Price Target to $164 from $168, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Close Higher on Thursday

05/12/2022 | 04:12pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMERISOURCEBERGEN CORPORATION 2.67% 148.46 Delayed Quote.8.81%
ASCENDIS PHARMA A/S -0.42% 91.09 Delayed Quote.-32.29%
CRISPR THERAPEUTICS AG 2.78% 66.96 Delayed Quote.-11.64%
NASDAQ COMPOSITE 3.34% 11607.62 Real-time Quote.-28.21%
PRIVIA HEALTH GROUP, INC. -1.11% 29.43 Delayed Quote.13.76%
WALGREENS BOOTS ALLIANCE, INC. 1.86% 41.65 Delayed Quote.-20.15%
All news about CRISPR THERAPEUTICS AG
06/23Oppenheimer Adjusts CRISPR Therapeutics Price Target to $122 From $150, Maintains Outpe..
MT
06/23Evercore ISI Downgrades CRISPR Therapeutics to In Line From Outperform, Lowers Price Ta..
MT
06/22Chardan Adjusts CRISPR Therapeutics' Price Target to $164 from $168, Keeps Buy Rating
MT
06/22WALL STREET STOCK EXCHANGE : Powell's tall order to reassure investors
06/22Stifel Adjusts CRISPR Therapeutics' Price Target to $55 from $57, Keeps Hold Rating
MT
06/22ANALYST RECOMMENDATIONS : Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
06/22Piper Sandler Adjusts Price Target on CRISPR Therapeutics to $121 From $115, Reiterates..
MT
06/21CRISPR THERAPEUTICS AG : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21CRISPR THERAPEUTICS : Innovation Day Presentation
PU
06/21TRANSCRIPT : CRISPR Therapeutics AG - Special Call
CI
More news
Analyst Recommendations on CRISPR THERAPEUTICS AG
More recommendations
Financials (USD)
Sales 2022 72,4 M - -
Net income 2022 -669 M - -
Net cash 2022 1 072 M - -
P/E ratio 2022 -7,73x
Yield 2022 -
Capitalization 5 187 M 5 187 M -
EV / Sales 2022 56,8x
EV / Sales 2023 20,2x
Nbr of Employees 473
Free-Float 98,4%
Chart CRISPR THERAPEUTICS AG
Duration : Period :
CRISPR Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 66,96 $
Average target price 115,30 $
Spread / Average Target 72,2%
EPS Revisions
Managers and Directors
Samarth Kulkarni Chief Executive Officer & Executive Director
Rodger Novak Chairman & President
Brendan Smith Chief Financial Officer
Jonathan Alexander Terrett Head-Research
Stephen R. Kennedy Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CRISPR THERAPEUTICS AG-11.64%5 187
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371